Will AstraZeneca's headache continue?
Thursday 27 April
Investors are already forewarned of a tough 2017 for pharmaceutical business AstraZeneca (AZN) after guidance in February for a low to mid-single digit sales decline.
We believe investors will want an update on cholesterol treatment Crestor in its trading update on 27 April after a 13% drop in sales following patent expiry.
The market will also be looking for clarity on which new drugs it will bring to market to replenish its portfolio.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell Youinvest.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Story In Numbers
- Most Popular Investment Trusts
- Most Popular Funds
- 255: WH Smith’s ever-increasing overseas exposure
- Zero: Hunting cannot provide earnings guidance
- Have UK employment levels peaked?
- Record ETF flows in the first quarter of 2017
- 76,230: Tesla largest US car maker by market cap
- 10 bagger: London Stock Exchange